@article{1bc546a9359b4cc8ad3be3922be46aba,
title = "Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: Proceedings from a workshop",
abstract = "The workshop discussions focused on how low-density lipoprotein cholesterol (LDL-C) goal attainment can be enhanced with the use of health information technology (HIT) in different clinical settings. A gap is acknowledged in LDL-C goal attainment, but because of the passage of the American Recovery & Reinvestment Act and the Health Information Technology for Economic and Clinical Health Acts there is now reason for optimism that this gap can be narrowed. For HIT to be effectively used to achieve treatment goals, it must be implemented in a setting in which the health care team is fully committed to achieving these goals. Implementation of HIT alone has not resulted in reducing the gap. It is critical to build an effective management strategy into the HIT platform without increasing the overall work/time burden on staff. By enhancing communication between the health care team and the patient, more timely adjustments to treatment plans can be made with greater opportunity for LDL-C goal attainment and improved efficiency in the long run. Patients would be encouraged to take a more active role. Support tools are available. The National Lipid Association has developed a toolkit designed to improve patient compliance and could be modified for use in an HIT system. The importance of a collaborative approach between nongovernmental organizations such as the National Lipid Association, National Quality Forum, HIT partners, and other members of the health care industry offers the best opportunity for long-term success and the real possibility that such efforts could be applied to other chronic conditions, for example, diabetes and hypertension.",
author = "Cohen, {Jerome D.} and Aspry, {Karen E.} and Brown, {Alan S.} and Foody, {Joanne M.} and Roy Furman and Jacobson, {Terry A.} and Karalis, {Dean G.} and Kris-Etherton, {Penny M.} and Ralph Laforge and O'Toole, {Michael F.} and Scott, {Ronald D.} and Underberg, {James A.} and Valuck, {Thomas B.} and Willard, {Kaye Eileen} and Ziajka, {Paul E.} and Ito, {Matthew K.}",
note = "Funding Information: Dr Cohen has received consulting fees from Merck & Co, Inc. Dr Aspry has no disclosures to report. Dr Brown has received speaker honoraria from Abbott Laboratories, Forest Pharmaceuticals, and Merck & Co Inc and is on the Advisory Board for Abbott Laboratories, Kowa Pharmaceuticals, Aegerion Pharmaceuticals, Inc, Merck & Co Inc, and Gilead. Dr Foody has received consulting fees from Merck & Co Inc, Pfizer Inc, Genzyme Corporation, and Sanofi. Dr Furman is employed by Intelligent Medical Decisions, Inc. Dr Jacobson has received consulting fees from AbbVie Inc, Amarin Corporation, Merck & Co Inc, Regeneron Pharmaceuticals, Inc, Sanofi, and Amgen, Inc. Dr Karalis has received speaker honorarium from GlaxoSmithKline. Dr Kris-Etherton has received research grants from The Peanut Institute, General Mills Inc, The Almond Board of California, Western Pistachio Association, Hass Avocado Board and has received honoraria from MonaVie LLC and Unilever. Mr LaForge is on the speaker{\textquoteright}s bureau for AstraZeneca. Dr O{\textquoteright}Toole has no disclosures to report. Dr Scott has no disclosures to report. Dr Underberg is on the speaker{\textquoteright}s bureau for Abbott Laboratories, Forest Pharmaceuticals, GlaxoSmithKline, Daiichi Sankyo, Inc, Kowa Pharmaceuticals, LipoScience, Inc, diaDexus, Inc, Merck and Co, and Eli Lilly & Co and has received consulting fees from Genzyme, News Corporation, Publicis, Inc, Guidepoint Global, Amarin Corporation, and Aegerion Pharmaceuticals, Inc. Dr Valuck has no disclosures to report. Dr Willard has no disclosures to report. Dr Ziajka has received speaker honoraria from Kowa Pharmaceuticals, Abbott Laboratories, Merck & Co, Inc, Hunter Heart Laboratory, Atherotech, Inc, and AstraZeneca. Dr Ziajka has received a research grant from Genzyme Corporation and has received consulting fees from Hunter Heart Lab. Dr Ito has received speaker honoraria from GlaxoSmithKline, Kowa Pharmaceuticals, and Abbott Laboratories. Overall support for this workshop was provided by Merck & Co, Inc. ",
year = "2013",
doi = "10.1016/j.jacl.2013.10.002",
language = "English (US)",
volume = "7",
pages = "573--609",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier Ltd",
number = "6",
}